Join
Live feed
·
PRReleasevia Quantisnow
Soleno Therapeutics Inc. logo

Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome

ByQuantisnow·Wall Street's wire, on your screen.
SLNO· Soleno Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SLNO (Soleno Therapeutics Inc.) and more on Quantisnow.